News

Under the deal, Teva will be responsible for all US commercial activities for the product including promotion and distribution, while Eagle’s responsibility include securing all regulatory approvals, conducting

The research collaboration and license agreement will see new small-molecule therapies directed against the nuclear hormone receptors called ROR gamma (t) to treat these disorders. As part of

Under the deal, Celon will supply the product to Lupin, which will be responsible for its commercialization in the US, Canada, Mexico and other key markets. GSK’s Advair

Under the deal, Agilvax will use Humabs’ antibodies developed from patient survivors of infectious and chronic diseases. The collaboration will contribute to the rapid advancement of Agilvax’s expanding

Lightlake is focused on developing addiction treatments based on its expertise in opioid antagonists. In December 2014, Lightlake in partnership with the National Institute on Drug Abuse (NIDA),

The company noted that the FDA approved prescription treatment option is now available in pharmacies nationwide for patients with rosacea, a common, inflammatory disorder affecting the face. The

A total of 2,021 patients were enrolled in the both the randomized, double-blind, placebo-controlled, multi-centered trials at participating clinics and practices in the Americas, Europe, Australia, New Zealand

Under the deal, the two parties will collaborate on an NIH-sponsored Phase II trial of AV-101, VistaGen’s orally-active NMDA receptor modulator, in MDD patients. MDD is a debilitating

The injection is indicated for prophylaxis of deep vein thrombosis (DVT) in patients undergoing abdominal surgery, hip or knee replacement surgery, or in medical patients with severely restricted